Watchmaker Genomics, Inc.

Founded in 2019 by Co-Founder and CEO Trey Foskett, and based in Colorado, US, Watchmaker Genomics, Inc. operates as a biotechnology company that engages in applying enzyme technology to do research like reading, writing, and editing DNA. In June 2022, Watchmaker Genomics, Inc. raised USD 40 million in Series A funding led by Decheng Capital with participation from another new investor Eclipse Ventures.

The Series A funding values Watchmaker Genomics at USD 242. 25 million post-money. Watchmaker combines protein engineering with large-scale enzyme manufacturing to address the requirements of high-growth clinical genomics applications. The company's product portfolio includes enzymes and kits for next-generation sequencing library preparation, synthetic biology, and molecular diagnostics.

It also offers Watchmaker RNA Library Prep Kit, Watchmaker RNA Library Prep Kits with Polaris Depletion, Equinox Library Amplification Kits, and StellarScript™ Reverse Transcriptase (RT). The company plans to use the funding raised in 2022 to accelerate investment in its protein engineering platform to deliver a suite of new products that address the demands of clinical sequencing and support emerging applications in single-cell analysis, epigenetics, and cell-free DNA. It also plans to handle an increase in sales, work, or output in a cost-effective, reasonable manner to meet the demand in its industry.